Drug intelligence / Profile preview

hwh340

Development stage: Phase 1
Lead developer: Humanwell Healthcare
Modality: Small Molecules
Administration: Oral

Overview

HWH340 is a potent PARP (poly ADP-ribose polymerase) inhibitor being developed for the treatment of solid tumors, particularly those with BRCA deficiencies. Preclinical studies have demonstrated promising antitumor activity in tumor models, along with favorable pharmaceutical properties. The drug works by inhibiting PARP enzymes, which are involved in DNA repair, leading to synthetic lethality in cancer cells with deficiencies in homologous recombination repair pathways, such as those with BRCA1/2 mutations.

Targets

PARP2 (Poly (adp-ribose) polymerase 2)

Beyond the preview

Go deeper on hwh340.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hwh340.

Explore the full profile